From Medscape Oncology

Coverage from the

American Society of Hematology (ASH) 2016 Annual Meeting

December 03 - 06, 2016; San Diego, California

December 03 - 06, 2016 San Diego, California
  • Stopping Drug Therapy for CML: EURO-SKI Results This is the largest cohort to date of patients with chronic myeloid leukemia followed after stopping treatment with tyrosine kinase inhibitors.
  • ASH CAR T Cells Motoring to Market -- by Next Year? Pivotal registration trials for CAR T cell therapies have now been completed, and two products could be approved by the end of 2017.
  • ASH Obinutuzumab Bests Rituximab in Advanced FL Obinutuzumab for induction and maintenance was better than the current standard of care for follicular lymphoma, but caution is warranted with chemotherapy used as part of induction.

Meeting Highlights at a Glance

  • Top News From ASH 2016: Slideshow Top News From ASH 2016: Slideshow Practice-changing research in lymphoma and leukemia, plus growing excitement over two chimeric antigen receptor (CAR) T cell products, featured prominently at this year's meeting.

Conference News

Popular ASH 2015 News

Medscape Oncology©  WebMD, LLC

Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.


Pre-Meeting Commetary

Previous Coverage